Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769714 · ClinicalTrials.gov registry record · Phase 4
EXPAREL for Minimally Invasive Supracervical Hysterectomies
A Phase 4 study, sponsored by Maimonides Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT03769714 is a Phase 4 study that has completed, run by Maimonides Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT03769714, a Phase 4 study, has completed, sponsored by Maimonides Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The aim of the of the study is a reduction in minimally invasive supracervical hysterectomy postsurgical pain, which may result in less need for supplemental opioid pain medications, fewer opioid related adverse events, and a better recovery experience for patients, which may offer an economic benefit to health care systems. Intracervical preoperative dose of Exparel during minimally invasive (robotic--assisted or traditional laparoscopy) supracervical hysterectomy reduces cumulative pain scores for up to 24 hours and reduces overall requests for break through (additional) analgesia with opioid consumption compared with placebo.
Interventions
- DRUG Exparel
- DRUG Saline Solution for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03769714
The ClinicalTrials.gov registry entry for NCT03769714 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT03769714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03769714 about?
NCT03769714 is a clinical study titled "EXPAREL for Minimally Invasive Supracervical Hysterectomies". The aim of the of the study is a reduction in minimally invasive supracervical hysterectomy postsurgical pain, which may result in less need for supplemental opioid pain medications, fewer opioid related adverse events, and a better recovery experience for patients, which may offer an economic benef...
What is the current status of trial NCT03769714?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2018-10-01. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT03769714?
The interventions under investigation include: Exparel (DRUG), Saline Solution for Injection (DRUG).
Who is sponsoring clinical trial NCT03769714?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.